HPLC–MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
- 15 November 2007
- journal article
- Published by Elsevier in Journal of Chromatography B
- Vol. 859 (2) , 234-240
- https://doi.org/10.1016/j.jchromb.2007.10.003
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1AIDS, 2007
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)HIV Medicine, 2006
- Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitorsAIDS, 2006
- An Update on Therapeutic Drug Monitoring for Antiretroviral DrugsTherapeutic Drug Monitoring, 2006
- Effectiveness of Nonpeptide Clinical Inhibitor TMC-114 on HIV-1 Protease with Highly Drug Resistant Mutations D30N, I50V, and L90MJournal of Medicinal Chemistry, 2006
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005)HIV Medicine, 2005
- TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Chromatography B, 2004
- Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2003
- Therapeutic drug monitoring in HIV infection: current status and future directionsAIDS, 2002